CLBT Stock Forecast 2025-2026
Distance to CLBT Price Targets
CLBT Price Momentum
10 Quality Stocks Worth Considering Now
Researching Cellebrite (CLBT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CLBT and similar high-potential opportunities.
Latest CLBT Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, CLBT has a bullish consensus with a median price target of $28.00 (ranging from $26.00 to $29.00). Currently trading at $19.56, the median forecast implies a 43.1% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Frank Takkinen at Lake Street, suggesting a 32.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLBT Analyst Ratings
CLBT Price Target Range
Latest CLBT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLBT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 2, 2025 | Needham | Mike Cikos | Buy | Reiterates | $28.00 |
| Mar 27, 2025 | Needham | Mike Cikos | Buy | Reiterates | $28.00 |
| Mar 10, 2025 | Needham | Mike Cikos | Buy | Reiterates | $28.00 |
| Feb 14, 2025 | Needham | Mike Cikos | Buy | Reiterates | $28.00 |
| Feb 14, 2025 | Lake Street | Frank Takkinen | Buy | Maintains | $26.00 |
| Feb 11, 2025 | JP Morgan | Brian Essex | Overweight | Maintains | $28.00 |
| Jan 22, 2025 | Needham | Mike Cikos | Buy | Maintains | $28.00 |
| Dec 16, 2024 | JP Morgan | Brian Essex | Overweight | Maintains | $24.00 |
| Nov 7, 2024 | Needham | Mike Cikos | Buy | Maintains | $21.00 |
| Nov 7, 2024 | Craig-Hallum | Jeff Van Rhee | Buy | Maintains | $24.00 |
| Nov 7, 2024 | JP Morgan | Brian Essex | Overweight | Maintains | $22.00 |
| Sep 25, 2024 | Craig-Hallum | Jeff Van Rhee | Buy | Maintains | $23.00 |
| Sep 23, 2024 | TD Cowen | Shaul Eyal | Buy | Maintains | $23.00 |
| Aug 16, 2024 | Craig-Hallum | Jeff Van Rhee | Buy | Maintains | $20.00 |
| Aug 16, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $17.00 |
| Aug 16, 2024 | Needham | Mike Cikos | Buy | Maintains | $17.00 |
| Aug 16, 2024 | B of A Securities | Tal Liani | Buy | Maintains | $17.00 |
| Aug 16, 2024 | Deutsche Bank | Jamie Shelton | Buy | Maintains | $18.00 |
| Aug 16, 2024 | JP Morgan | Brian Essex | Overweight | Maintains | $17.00 |
| Aug 14, 2024 | JP Morgan | Brian Essex | Overweight | Maintains | $15.00 |
Cellebrite DI Ltd. (CLBT) Competitors
The following stocks are similar to Cellebrite based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cellebrite DI Ltd. (CLBT) Financial Data
Cellebrite DI Ltd. has a market capitalization of $4.56B with a P/E ratio of 69.1x. The company generates $401.20M in trailing twelve-month revenue with a -70.5% profit margin.
Revenue growth is +17.2% quarter-over-quarter, while maintaining an operating margin of +14.4% and return on equity of -152.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Cellebrite DI Ltd. (CLBT) Business Model
About Cellebrite DI Ltd.
Provides digital intelligence solutions for investigations.
Cellebrite DI Ltd. earns revenue by offering advanced software solutions and services that assist law enforcement, government agencies, and enterprises in analyzing digital data. Their products enable the extraction, deciphering, and analysis of information from mobile devices, which is critical for investigations and operational efficiency.
Headquartered in Israel, Cellebrite is recognized for its technological innovation in digital forensics, contributing to cybersecurity, legal investigations, and data recovery. The company's solutions help improve public safety by enhancing the integrity and security of digital data in various sectors.
Company Information
Sector
Technology
Industry
Software - Infrastructure
Employees
1,167
CEO
Mr. Thomas E. Hogan
Country
Israel
IPO Year
2020
Website
www.cellebrite.comCellebrite DI Ltd. (CLBT) Latest News & Analysis
Latest News
Cellebrite (NASDAQ: CLBT) will release its Q1 2025 financial results on May 14, 2025, before the market opens, as announced on April 10, 2025.
Cellebrite's upcoming Q1 2025 financial results may impact its stock performance and investor sentiment, providing insights into its growth and operational health.
The Company held its inaugural sold-out Case-to-Closure User Summit, celebrating excellence in digital investigations with over 700 attendees.
The sold-out summit indicates strong industry interest and engagement, suggesting potential growth and revenue opportunities for the company in the digital investigations sector.
Cellebrite (Nasdaq: CLBT) has filed its Annual Report on Form 20-F for the year ended December 31, 2024, with the SEC, as announced on March 18, 2025.
Cellebrite's filing of its Annual Report indicates compliance with SEC regulations, which can enhance investor confidence and impact stock performance.
Investors in the Technology Services sector may consider Smiths Group PLC (SMGZY) and Cellebrite DI Ltd. (CLBT) as potential undervalued stock options.
The mention of Smiths Group PLC and Cellebrite DI Ltd. highlights potential investment opportunities in the undervalued Technology Services sector, signaling possible gains for savvy investors.
After Plunging -17.61% in 4 Weeks, Here's Why the Trend Might Reverse for Cellebrite DI Ltd. (CLBT)
1 month agoCellebrite DI Ltd. (CLBT) is now technically considered oversold, indicating a potential exhaustion of heavy selling pressure on the stock.
Cellebrite DI Ltd. being technically oversold suggests a potential rebound opportunity, indicating reduced selling pressure and possible future price appreciation for investors.
Is This Stock a Next-Gen Digital Forensics Leader?
2 months agoCellebrite (CLBT) is discussed for its role in digital forensics, with insights on growth potential, management, and financials to aid investment decisions.
Cellebrite's insights on growth potential and management performance can influence stock valuation, impacting investment decisions and market sentiment around CLBT.
Frequently Asked Questions About CLBT Stock
What is Cellebrite DI Ltd.'s (CLBT) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Cellebrite DI Ltd. (CLBT) has a median price target of $28.00. The highest price target is $29.00 and the lowest is $26.00.
Is CLBT stock a good investment in 2025?
According to current analyst ratings, CLBT has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $19.56. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CLBT stock?
Wall Street analysts predict CLBT stock could reach $28.00 in the next 12 months. This represents a 43.1% increase from the current price of $19.56. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cellebrite DI Ltd.'s business model?
Cellebrite DI Ltd. earns revenue by offering advanced software solutions and services that assist law enforcement, government agencies, and enterprises in analyzing digital data. Their products enable the extraction, deciphering, and analysis of information from mobile devices, which is critical for investigations and operational efficiency.
What is the highest forecasted price for CLBT Cellebrite DI Ltd.?
The highest price target for CLBT is $29.00 from at , which represents a 48.3% increase from the current price of $19.56.
What is the lowest forecasted price for CLBT Cellebrite DI Ltd.?
The lowest price target for CLBT is $26.00 from Frank Takkinen at Lake Street, which represents a 32.9% increase from the current price of $19.56.
What is the overall CLBT consensus from analysts for Cellebrite DI Ltd.?
The overall analyst consensus for CLBT is bullish. Out of 11 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $28.00.
How accurate are CLBT stock price projections?
Stock price projections, including those for Cellebrite DI Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.